Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere Subsidiary Given SFDA Approval for anti-TNF Biosimilar

publication date: May 9, 2011
Simcere Pharma reported that Shanghai Celgen Bio-Pharma, was granted SFDA approval for Qiangke. Simcere owns 35% of Shanghai Celgen. Qiangke is a Recombinant Human TNF Receptor-IgG Fusion Protein for Injection, which Simcere says is indicated for ankylosing spondylitis. Ankylosing spondylitis is a chronic inflammation of the spine that can restrict mobility. The drug is also used to treat other automimmune diseases as well. The approval came just in time. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital